FDA Issues Draft Guidance for Pharmacogenomic Data Submissions
The US Food and Drug Administration issued a draft guidance, Pharmacogenomic Data Submissions Companion Guidance to be used as a companion to an earlier guidance, Pharmacogenomic Data Submissions, which was issued in March 2005.
Rockville, MD (Aug. 29)-The US Food and Drug Administration issued a draft guidance, Pharmacogenomic Data Submissions Companion Guidance, to be used as a companion to an earlier guidance, Pharmacogenomic Data Submissions, which was issued in March 2005. The draft guidance explains the procedure for voluntary genomic data submissions and marketing submissions containing genomics data. These submissions can be part of investigational new drug applications, new drug applications, and biologics license applications. The recommendations are intended to facilitate progress in pharmacogenomics and pharmacogenomic data use in drug development.
The draft guidance addresses methodological issues that should be considered when submitting gene expression data from microarrays, including:
• RNA isolation, handling, and characterization
• Labeling systems
• Hybridizations for microarrays
• Fluorescence reader settings for microarrays
• Differentially expressed genes
• Genotyping
• Proficiency testing.
Comments about the draft guidance are due Nov. 27, 2007. Notice of the draft guidance was published in Federal Register 72 (167), 49722–49723 (2007).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
